However, because there is a lack of reliable clinical data to confirm PARPis are suitable for treating all types of cancer, patients should have genetic testing for defects in BRCA1/2 and other genes related to homologous recombination deficiency, before PARPis are safely applied [46]. Here, BRCA1 is linked to cancer.